Yingli Green Energy Hold. Co. Ltd. (ADR) (NYSE: YGE) shares increased 9.18% to $3.33 after the company announced that the Company has supplied 65 kilowatts of PV modules for Kawkabuna for Energy Solutions ("Kawkabuna"), which is a specialized company in Jordan providing energy saving solutions. This is Yingli Green Energy's first order in the Jordanian market.
Additionally, YGE’s stock was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research note issued to investors on Jan. 30. The firm currently has a $3.10 price target on the stock.
Harmony Gold Mining Co. (ADR) (NYSE: HMY) stock gained 6.55% to $6.99 after the company announced that the Board has approved and declared an interim dividend of ZAR 0.50 per ordinary share (gross) in respect of the six months ended December 31, 2012. The dividend is referred to as Dividend No. 85. The dividend has been declared payable on March 11, 2013 to those shareholders recorded in the books of the Company at the close of business on March 8, 2013.
Humana Inc. (NYSE: HUM) shares climbed 3.78% to $78.20 after the company today reported lower fourth-quarter earnings that still exceeded analysts' expectations as the company kept control of rising costs. The company said that net income had fallen to $192 million, or $1.19 a share, from $199 million, or $1.20 per share, a year earlier. Analysts on average had expected earnings of $1.06 per share. Fourth-quarter revenue rose 6% to $9.56 billion from $9.06 billion, missing the analysts' average estimate of $9.73 billion.
Ciena Corporation (NASDAQ: CIEN) stock increased 2.53% to $16.27 after the company, on Feb. 1, announced that proxy materials for its 2013 Annual Meeting of Stockholders to be held Wednesday, March 20, 2013 at 3:00 p.m. Eastern time are now available via the Internet. In addition to providing proxy materials online, this year's Annual Meeting will be Ciena's first completely virtual meeting of stockholders to be webcast live over the Internet.
Peregrine Pharmaceuticals (NASDAQ: PPHM) shares gained 1.42% to $2.15. The company, on Jan. 7, provided an update from its internal review of discrepancies from its Phase II randomized, double-blind placebo-controlled trial of bavituximab in second-line non-small cell lung cancer (NSCLC) in 121 patients.
Csrnewsdaily.com has a finger on the pulse of many sectors including renewable energy, oil, pharma, mining, finance, and healthcare. Our in depth research and analysis of NASDAQ, OTCBB, Pink Sheets, and NYSE has yielded considerable gains for our subscribers.
Our to-the-minute reports and alerts coupled with breaking news, analysis, investment strategies, and FREE subscription email services contribute to our role as one of the leading investor relations marketing firms.
The assembled information disseminated by Csrnewsdaily.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Csrnewsdaily.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Pacific Dynasty Consultants Inc.
2637 E Atlantic Blvd #22611 Pompano Beach, FL 33062